Building upon the standard of care in adjuvant therapy of high-risk melanoma

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8559-8563

  Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; IMMUNOSTIMULATING AGENT; ISOTRETINOIN; OLIGONUCLEOTIDE; PLACEBO; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MEGADOSE; EDITORIAL; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MELANOMA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR VOLUME; HEAD AND NECK TUMOR; NOTE; PATHOLOGY; RISK FACTOR; STANDARD; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; MELANOMA; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME;

EID: 33644836863     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.8168     Document Type: Editorial

References (36)

1. Jemal A, Murray T, Ward E, et al: Cancer Statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
3. Kirkwood JM, Ibrahim J, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
4. Richtig E, Soyer HP, Posen M, et al: Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol 23:8655-8663, 2005
5. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
6. Wang E, Miller L, Ohnmacht G, et al: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586, 2002
7. Kirkwood JM., Lee S, Land S, et al: E1696: Final analysis of the clinical and immunological results of a multi-center ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) (MGT) +/-IFNa2b and GM-CSF. Proc Am Soc Clin Oncol 22:710s, 2004 (abstr 7502)
8. Keilholz U, Weber J, Finke J, et al: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97-138, 2002
9. Ernstoff MS, Gooding W, Nair S, et al: Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 52:851-856, 1992
10. Hakansson A, Gustafsson B, Krysander L, et al: Tumor-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74:670-676, 1996
11. Kirkwood JM, Wilson J, Whiteside T, et al: Antitumor and immunomodulatory effects of intradermal picibanil (OK-432): Results of a phase IA trial and status of a phase IB trial in high-risk melanoma. Cancer Invest 10:20-21, 1992 (suppl 1, abstr 19)
12. Moschos S, Edington H, Rao AR, et al: High dose interferon-alfa 2b (HDI): Toxicity, response, and predictive markers in a trial of neoadjuvant therapy for regional lymph node metastatic melanoma. Proc Am Soc Clin Oncol 23:714S, 2005 (abstr 7517)
13. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al: A-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934-5937, 2004
14. Clemente CG, Mihm MC Jr, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310, 1996
15. Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54, 2004
16. Gabrilovich D: Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat Rev Immunol 4:941-952, 2004
17. Nordlund JJ, Kirkwood JM, Forget BM: Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 9:689-696, 1983
18. Atkins M, Mier JW, Parkinson DR, et al: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563, 1988
19. Tsoutsos D, Ioannovich J, Frangia K, et al: The prevalence and prognostic significance of autoantibodies detected in patients with high risk melanoma receiving adjuvant therapy with high-dose interferon. Proc Am Soc Clin Oncol 23:714s, 2005 (abstr 7519)
20. Hancock BW, Wheatley K, Harris S, et al: Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom coordinating committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53-61, 2004
21. Moschos SJ, Kirkwood JM, Konstantinopoulos PA: Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 22:11-14, 2004
22. Cameron D, Cornbleet M: Adjuvant interferon alpha 2b in high-risk melanoma: The Scottish Study. Br J Cancer 84:1146-1149, 2001
23. Pehamberger H, Soyer P, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425-1429, 1998
24. Grob JJ, Dreno B, de la Salmonière P, et al: Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1-5 mm without clinically detectable node metastases. Lancet 351:1905-1910, 1998
25. Cascinelli N, Belli F, Mackie RM, et al: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 358:866-869, 2001
26. Hancock BW, Wheatley K, Harrison G, et al: Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Co-Ordinating Committee on Cancer Res (UKCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. Proc Am Soc Clin Oncol 20:349a, 2001 (abstr 1393)
27. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88:1484-1491, 2000
28. Morton DL: Lympathatic mapping and sentinel lymphadenectomy for melanoma: Past, present, and future. Ann Surg Oncol 8:22S-28S, 2001 (suppl)
29. Balch CM, Soong S, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
30. Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph bode status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
31. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
32. Tatsumi T, Kierstead L, Ranieri E, et al: Disease-associated bias in T helper Type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRBI 0401+ patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628, 2002
33. Tatsumi T, Kierstead L, Ranieri E, et al: MAGE-6 encodes HLA-DRB1 *0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 9:947-954, 2003
34. Topalian SL, Rivoltini L, Mancini M, et al: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A 91:9461-9465, 1994
35. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV Melanoma. J Clin Oncol 23:741-750, 2005
36. Lang KS, Recher M, Junt T, et al: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11:138-145, 2005